 B. High-risk LCH with measurable disease failure of front-line therapy. C. Low-risk LCH with measurable disease failure of second-line therapy. D. LCH-ND no previous therapy required. E. Other measurable solid tumors e.g., melanoma, Wilms tumor, papillary thyroid carcinoma refractory to, relapsed after, or intolerant to standard therapy or for whom no standard therapy exists. 